PPI-targeted Drug Discovery

MAGNA™ – Revealing
the underlying biology
of protein-protein
interactions

MAGNA™ – Revealing the underlying biology of protein-protein interactions

MAGNA™ will play a key role in advancing the rapidly emerging field of protein-protein interactions

Protein–protein interactions (PPIs) play pivotal roles in the processes of life, including signal transduction, growth, and cell differentiation. There are thought to be more than 600,000 distinct PPIs in humans, and aberrant PPIs are associated with cancer,  autoimmune conditions and neurodegenerative diseases. PPIs represent a fast–emerging class of drug targets, with multiple drugs approved or in late-stage clinical development. However, the enormous potential of this field is limited by a poor understanding of the complex, dynamic nature of protein interactions due to ineffective analytical techniques.

MAGNA™ can dramatically advance the field of protein-protein interactions

MAGNA™ is a versatile platform for analyzing protein-protein interactions with a straightforward and scalable assay. It has clear benefits over existing single molecule approaches which are either unable to detect low force interactions (for example, atomic force microscopy) or lack scalability (optical tweezers).

    • Modular approach enables a wide interchangeable range of binders (antibodies, aptamers, nucleic acids)
    • Multiplexing capability enables multiple interaction pairs to be studied in a single run
    • Precisely measure the binding kinetics and biological variability of PPIs and PPI modulating drug compounds

MAGNA™ will be the first tool capable of analyzing PPIs in kinetic detail and at scale